Call Today for a FREE Confidential Case Review - Toll-Free 24/7 (866) 920-0753

Tradjenta Lawsuit

Tradjenta Lawsuit

Although Boehringer Ingelheim’s diabetes medication Tradjenta (linagliptin) has been linked to pancreatitis, pancreatic cancer, and rhabdomyolysis.

What You Can Do & How We Can Help

The Schmidt Firm, PLLC is currently accepting Tradjenta induced injury cases in all 50 states. If you or somebody you know was diagnosed with pancreatic cancer, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call us toll-free 24 hours a day at (866) 920-0753.

Tradjenta Side Effects

FDA Evaluating Rhabdomyolysis Risk

The FDA is evaluating a potential signals of a serious risk and new safety information linking DPP4 diabetes drugs and rhabdomyolysis. This potentially life-threatening kidney side effect was identified by the FDA Adverse Event Reporting System (FAERS) between April and June 2017.

UPDATE: FDA Warning Links Tradjenta and Severe Joint Pain

August 28, 2015 — The FDA is warning that Tradjenta may cause severe, disabling joint pain. Click here to read more.

FDA Investigating Tradjenta and Pancreatic Cancer

In an early Drug Safety Communication published in March 2013, the FDA warned about evidence suggesting a possible increased risk of pancreatitis and pancreatic cancer associated with Tradjenta and other incretin mimetic drugs. Click here to read more.

What is Tradjenta and How Does It Work?

The type-2 diabetes drug Tradjenta (linagliptin) helps patients regulate their blood-sugar levels. Specifically, it inhibits dipeptidyl peptidase-4 (DPP-4), which prevents the liver from releasing as much glucose (sugar) in the blood. Tradjenta also influences digestive hormones like glucagon-like peptide-1 (GLP-1), also known as incretins, which stimulate the pancreas to lower blood-sugar by making more insulin.

Tradjenta is one of the newest drugs in the incretin mimetic class. This class of drugs has been on the market since 2006, and Boehringer Ingelheim gained FDA-approval for Tradjenta in August 2012.

What is the problem with Tradjenta?

The problem with Tradjenta is that it may have long-term side effects like pancreatic cancer. These diseases are some of the most severe, life-threatening side effects that any medication can cause. Our lawyers are concerned that Boehringer Ingelheim is not adequately warning about the potential risk.

It is not unusual for new drugs to have unanticipated side effects, which is why many experts recommend taking precautions when new drugs are introduced. This is also why experts are so concerned about the evidence linking Tradjenta and pancreatic cancer. Unfortunately, research could take many years.

Tradjenta and Pancreatic Cancer

The active drug in Tradjenta, linagliptin, stimulates cell-growth in the pancreas. There is some evidence that this can cause inflammation (pancreatitis), which is why the Prescribing Information for Tradjenta warns about an increased risk of pancreatitis. Pancreatitis is also a risk-factor for pancreatic cancer, but cancer is harder to study because it often takes many years to develop.

One of the most important studies of incretin mimetic drugs and pancreatic cancer involved autopsies of pancreases from patients who were taking the drugs. The results of the study, which were published in Diabetes in March 2012, were alarming because they found evidence of pre-cancerous cellular changes.

Researchers found that one pancreas had a pre-cancerous growth in the pancreatic duct, which is where pancreatic cancer most often occurs. Three out of eight autopsied pancreases had adenomas, which are benign tumors made from glandular tissue. Unfortunately, even benign adenomas are dangerous because they must be removed surgically, with potentially devastating long-term complications like insulin injections. The researchers warned:

“Since the standard of care of a pancreatic neuroendocrine tumor, because of the risk of conversion to malignancy, even if benign, is surgical resection [i.e. removal], patients exposed to incretin therapy would seem to be at increased risk of requiring pancreatic surgery.”

Tradjenta Class Action Lawsuit

Our attorneys are not filing a Tradjenta class action. Instead, we are filing individual lawsuits. If you were diagnosed with pancreatic cancer, you could receive compensation for your medical expenses. Over 750 lawsuits involving pancreatic side effects of diabetes medications have been centralized in a federal Multi-District Litigation (MDL No. 2452) in California.

Do I have a Tradjenta Lawsuit?

The Schmidt Firm, PLLC is currently accepting Tradjenta induced injury cases in all 50 states. If you or somebody you know was diagnosed with pancreatic cancer, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call us toll-free 24 hours a day at (866) 920-0753.

Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.

 

Free Case Evaluation

The Schmidt Firm, PLLC has been recognized as one of the nation’s leading plaintiffs’ law firms and handles cases in all 50 states. We are very proud of our legal achievements, but equally self-respecting of our firm’s reputation for providing personal attention to each and every client we represent.

No matter what type of case you have, you may contact us with confidence by filling out the email contact form below or calling us directly by dialing toll free 24 hrs/day (866) 920-0753.

*
*
*